Close Menu

RXi Pharmaceuticals last week reported its second-quarter financial results, posting a more than 18 percent rise in its net loss on a nearly identical increase in operating costs.

For the three-month period ended June 30, RXi reported no revenues and a jump in its net loss to $5.1 million, or $0.37 per share, from $4.3 million, or $0.34 per share, a year earlier.

Research and development spending climbed to $3 million from $2.8 million, while general and administrative costs edged up to $2 million from $1.6 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.